Free Trial

Ocular Therapeutix (OCUL) Competitors

$6.29
+0.12 (+1.94%)
(As of 05/20/2024 ET)

OCUL vs. ARQT, LQDA, CNTA, OPK, BCYC, TYRA, ETNB, IMNM, ABVX, and SPRY

Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Arcutis Biotherapeutics (ARQT), Liquidia (LQDA), Centessa Pharmaceuticals (CNTA), OPKO Health (OPK), Bicycle Therapeutics (BCYC), Tyra Biosciences (TYRA), 89bio (ETNB), Immunome (IMNM), ABIVAX Société Anonyme (ABVX), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical preparations" industry.

Ocular Therapeutix vs.

Ocular Therapeutix (NASDAQ:OCUL) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership.

Ocular Therapeutix has a net margin of -192.61% compared to Arcutis Biotherapeutics' net margin of -204.35%. Ocular Therapeutix's return on equity of -76.64% beat Arcutis Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ocular Therapeutix-192.61% -76.64% -36.33%
Arcutis Biotherapeutics -204.35%-197.28%-60.67%

Ocular Therapeutix received 372 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 69.72% of users gave Ocular Therapeutix an outperform vote while only 62.07% of users gave Arcutis Biotherapeutics an outperform vote.

CompanyUnderperformOutperform
Ocular TherapeutixOutperform Votes
426
69.72%
Underperform Votes
185
30.28%
Arcutis BiotherapeuticsOutperform Votes
54
62.07%
Underperform Votes
33
37.93%

In the previous week, Arcutis Biotherapeutics had 17 more articles in the media than Ocular Therapeutix. MarketBeat recorded 21 mentions for Arcutis Biotherapeutics and 4 mentions for Ocular Therapeutix. Arcutis Biotherapeutics' average media sentiment score of 0.70 beat Ocular Therapeutix's score of -0.22 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocular Therapeutix
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcutis Biotherapeutics
8 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

59.2% of Ocular Therapeutix shares are owned by institutional investors. 5.5% of Ocular Therapeutix shares are owned by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ocular Therapeutix has higher earnings, but lower revenue than Arcutis Biotherapeutics. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$58.44M16.64-$80.74M-$1.35-4.65
Arcutis Biotherapeutics$59.61M18.57-$262.14M-$2.93-3.26

Ocular Therapeutix presently has a consensus target price of $15.17, suggesting a potential upside of 142.67%. Arcutis Biotherapeutics has a consensus target price of $27.00, suggesting a potential upside of 182.43%. Given Arcutis Biotherapeutics' higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Ocular Therapeutix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Arcutis Biotherapeutics
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75

Ocular Therapeutix has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

Summary

Ocular Therapeutix beats Arcutis Biotherapeutics on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCUL vs. The Competition

MetricOcular TherapeutixPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$972.71M$6.62B$4.93B$7.99B
Dividend YieldN/A2.72%44.82%3.91%
P/E Ratio-4.6510.00117.6214.81
Price / Sales16.64246.442,468.4573.68
Price / CashN/A20.5032.2329.27
Price / Book7.956.005.024.56
Net Income-$80.74M$136.27M$101.60M$212.43M
7 Day Performance11.35%7.14%5.41%4.87%
1 Month Performance20.31%10.47%9.46%9.25%
1 Year Performance-2.79%-1.49%9.72%10.45%

Ocular Therapeutix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARQT
Arcutis Biotherapeutics
2.1403 of 5 stars
$8.13
+1.8%
$26.56
+226.6%
-2.9%$939.26M$59.61M-2.07296Earnings Report
LQDA
Liquidia
1.9075 of 5 stars
$11.96
-1.5%
$21.00
+75.6%
+53.1%$927.29M$17.49M-9.97145Analyst Revision
CNTA
Centessa Pharmaceuticals
1.765 of 5 stars
$9.04
+2.4%
$10.00
+10.6%
+93.2%$910.69M$6.85M-5.7675Positive News
OPK
OPKO Health
4.3416 of 5 stars
$1.31
+3.2%
$3.17
+142.7%
-14.8%$909.57M$863.50M-3.733,930Insider Buying
Options Volume
BCYC
Bicycle Therapeutics
2.4687 of 5 stars
$21.85
-3.2%
$46.86
+114.4%
-12.7%$965.52M$41.61M-4.91284
TYRA
Tyra Biosciences
1.4345 of 5 stars
$18.58
+0.4%
$23.50
+26.5%
+26.4%$976.19MN/A-11.0649
ETNB
89bio
2.2289 of 5 stars
$9.09
+4.5%
$28.71
+215.9%
-49.2%$894.27MN/A-4.5270Earnings Report
Analyst Forecast
IMNM
Immunome
1.3105 of 5 stars
$14.72
-5.7%
$30.50
+107.2%
+148.5%$882.32M$14.02M-2.7355Analyst Revision
ABVX
ABIVAX Société Anonyme
1.8896 of 5 stars
$13.85
-0.7%
$32.00
+131.0%
N/A$871.58MN/A0.0061Analyst Forecast
News Coverage
Gap Up
SPRY
ARS Pharmaceuticals
2.6496 of 5 stars
$8.98
+1.0%
$18.50
+106.0%
+5.4%$870.07M$30,000.00-17.2724

Related Companies and Tools

This page (NASDAQ:OCUL) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners